Every 8-K that Alumis Inc (ALMS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALMS filings page.
Alumis Inc. (ALMS) reported topline results from its Phase 2b LUMUS trial of oral TYK2 inhibitor envudeucitinib in moderate-to-severe systemic lupus erythematosus. The randomized, double-blind, placebo-controlled study enrolled 408 patients across four arms and did not meet its primary BICLA endpoint or key secondary endpoints in the overall intent-to-treat population.
Alumis highlighted a prespecified IFNGS-high subgroup, which represents a majority of moderate-to-severe SLE patients, where envudeucitinib showed robust clinical responses across BICLA, SRI‑4, CLASI‑50, LLDAS, steroid reduction and joint improvement. Pharmacodynamic data showed dose‑dependent interferon‑pathway inhibition with maximal suppression at 40 mg BID. Envudeucitinib was generally well tolerated, with no new safety signals, no MACE or malignancies, and lower overall TEAE rates versus placebo. Alumis plans End‑of‑Phase 2 meetings with FDA and EMA to discuss a Phase 3 program in IFNGS‑high SLE and remains on track to submit a 2026 fourth‑quarter NDA for envudeucitinib in moderate‑to‑severe plaque psoriasis.
Alumis Inc. reported second quarter 2026 results and clinical progress. In the ONWARD3 long-term psoriasis study, 54% of patients achieved complete skin clearance (PASI 100) at 48 weeks, supporting envudeucitinib’s potential as a differentiated oral therapy in moderate-to-severe plaque psoriasis. The company plans to submit a New Drug Application in Q4 2026 and anticipates potentially pivotal Phase 2b LUMUS topline data in systemic lupus erythematosus (SLE) in Q3 2026.
For the quarter ended June 30, 2026, Alumis generated $1.662 million in collaboration revenue and recorded a net loss of $142.2 million, compared with net income of $59.3 million a year earlier, which had included a large bargain purchase gain. Operating expenses were $150.5 million, including a $41.8 million intangible assets impairment loss. Research and development expenses were $85.3 million and general and administrative expenses were $23.4 million.
As of June 30, 2026, Alumis reported cash and cash equivalents of $63.7 million and current marketable securities of $438.6 million, with total assets of $560.6 million and stockholders’ equity of $452.2 million, providing a substantial capital base to support its TYK2-focused pipeline, including envudeucitinib and CNS-penetrant candidate A-005.
Alumis Inc. reported new long-term Phase 3 data for envudeucitinib, its oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis from the ONWARD3 long-term extension study. Among 773 patients receiving up to 48 weeks of continuous treatment, 75% achieved PASI 90 and 54% achieved PASI 100, indicating near-complete and complete skin clearance. An integrated analysis across 890 patients in the ONWARD program showed PASI 90 and PASI 100 rates of 66% and 47%, respectively, after 48 weeks of therapy.
The company states that envudeucitinib’s safety and tolerability profile remained consistent with earlier ONWARD1/2 trials and no new safety signals were observed. A total of 1,509 patients rolled over into ONWARD3 from the two core Phase 3 trials, reflecting a rollover rate above 85% from a Phase 3 program enrolling more than 1,700 patients. Alumis plans to submit a New Drug Application to the FDA for envudeucitinib in plaque psoriasis in the fourth quarter of 2026 and expects topline Phase 2b data in systemic lupus erythematosus in the third quarter of 2026.
Alumis Inc. held its 2026 Annual Meeting of Stockholders on June 30, 2026. As of the May 5, 2026 record date, 123,432,072 shares of voting common stock were outstanding and entitled to vote.
Stockholders elected James B. Tananbaum, Lynn Tetrault and Zhengbin (Bing) Yao as Class II directors to serve until the 2029 Annual Meeting of Stockholders. Stockholders also ratified the Audit Committee’s appointment of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, with 105,924,017 votes for, 283,113 against and 242,002 abstentions.
Alumis Inc. furnished an updated corporate presentation for investors, analysts, and other stakeholders. The presentation, dated June 2026, is available on the company’s website and attached as Exhibit 99.1.
The material is furnished, not filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
Alumis Inc. reported first quarter 2026 results and highlighted strong Phase 3 data for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis. For the quarter ended March 31, 2026, total revenue was $1,741 (in thousands) compared with $17,389 (in thousands) a year earlier, with a net loss of $93,053 (in thousands) versus $98,963 (in thousands).
The Phase 3 psoriasis study showed robust skin clearance, with PASI 90 responses of 68.0% and 62.1% and PASI 100 responses of 41.0% and 39.5% at Week 24, along with improvements in quality of life and symptoms. Alumis plans to submit a New Drug Application for envudeucitinib in plaque psoriasis in the fourth quarter of 2026 and anticipates potentially pivotal Phase 2b topline data in systemic lupus erythematosus in the third quarter of 2026. Cash, cash equivalents and marketable securities contributed to total assets of $671,588 (in thousands) as of March 31, 2026.
Alumis Inc. reported strong Phase 3 results for envudeucitinib, its oral TYK2 inhibitor for moderate-to-severe plaque psoriasis. In the ONWARD1 and ONWARD2 trials, high levels of skin clearance were achieved and deepened through 24 weeks, with meaningful quality-of-life and itch improvements emerging early.
By Week 24, PASI 90 skin clearance rates reached 68.0% and 62.1%, and PASI 100 complete clearance reached 41.0% and 39.5% in envudeucitinib-treated patients. Safety and tolerability were favorable and consistent with Phase 2 data, with mostly mild, manageable side effects and no new safety signals reported.
More than 1,700 adults were enrolled across the parallel Phase 3 trials, which also showed rapid improvement in difficult-to-treat scalp psoriasis. Alumis plans to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in the second half of 2026 and is running an ONWARD3 long-term extension and the LUMUS Phase 2b trial in systemic lupus erythematosus, with topline LUMUS data expected in the third quarter of 2026.
Alumis Inc. reported full-year 2025 results and major pipeline progress. Total revenue reached $24,050 thousand, driven by license and collaboration revenue, compared with no revenue in 2024. Operating expenses rose to $477,854 thousand, mainly from higher research and development and general and administrative costs.
Net loss narrowed to $243,325 thousand from $294,233 thousand, helped by a $187,907 thousand gain on bargain purchase and higher interest income. At December 31, 2025, Alumis held $89,670 thousand in cash and cash equivalents and $218,831 thousand in marketable securities.
The company highlighted positive Phase 3 topline results for envudeucitinib in moderate-to-severe plaque psoriasis and plans to submit an NDA in 2H 2026. Potentially pivotal Phase 2b topline data in systemic lupus erythematosus are anticipated in 3Q 2026. Alumis also completed an upsized public offering in January 2026, raising $345,1 million in gross proceeds.
Alumis Inc. reported that its preliminary unaudited cash, cash equivalents and marketable securities totaled approximately $308.6 million as of December 31, 2025. This figure is management’s estimate and has not been audited, reviewed or examined by PricewaterhouseCoopers LLP and may change once the quarter- and year-end closing process is completed.
The company also entered into an underwriting agreement for a public offering of 17,650,000 shares of its common stock at $17.00 per share$345.1 million before underwriting discounts, commissions and expenses. The offering is expected to close on January 9, 2026, and the underwriters’ 30‑day option to purchase up to 2,647,500 additional shares was exercised in full on January 8, 2026.
Alumis Inc. filed a report describing new communications about its oral psoriasis therapy envudeucitinib. The company issued a press release titled “Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program” and furnished it as an exhibit. Alumis also posted an updated corporate presentation for investors and attached it as a separate exhibit.
The report notes that these materials contain forward-looking statements, including Alumis’s plans to submit a new drug application in the second half of 2026 and the potential for envudeucitinib to address IL-23/IL-17–driven diseases and those driven by Type I interferon. Alumis cautions that regulatory decisions, clinical trial outcomes, funding, and intellectual property protection could cause actual results to differ from these expectations.
Alumis Inc. filed a current report stating that it issued a press release on November 13, 2025, to announce its financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and provides details on the company’s operations and financial condition for the period.
The company also identifies Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document. The report is signed by Martin Babler, President and Chief Executive Officer of Alumis Inc.
Alumis Inc. filed a current report to note that it has updated its corporate presentation for use in meetings with investors, analysts, and other audiences as of September 2025. The updated presentation is included as Exhibit 99.1 to the report on Form 8-K.
The company states that the information in the report and the attached presentation is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and will not automatically be incorporated by reference into other securities law filings unless specifically referenced.
Alumis Inc. furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states that the information in Item 2.02 and Exhibit 99.1 is furnished and therefore is not deemed to be "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The report is signed by Martin Babler, President and Chief Executive Officer.